| Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung … YK Chae, A Arya, W Iams, MR Cruz, S Chandra, J Choi, F Giles Journal for immunotherapy of cancer 6, 1-27, 2018 | 410 | 2018 |
| Immunotherapeutic approaches for small-cell lung cancer WT Iams, J Porter, L Horn Nature Reviews Clinical Oncology 17 (5), 300-312, 2020 | 251 | 2020 |
| Epithelial-mesenchymal transition (EMT) signature is inversely associated with T-cell infiltration in non-small cell lung cancer (NSCLC) YK Chae, S Chang, T Ko, J Anker, S Agte, W Iams, WM Choi, K Lee, ... Scientific reports 8 (1), 2918, 2018 | 220 | 2018 |
| Small cell lung cancer, version 2.2022, NCCN clinical practice guidelines in oncology AKP Ganti, BW Loo, M Bassetti, C Blakely, A Chiang, TA D'Amico, ... Journal of the National Comprehensive Cancer Network 19 (12), 1441-1464, 2021 | 184 | 2021 |
| Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies DB Johnson, CM Lovly, M Flavin, KS Panageas, GD Ayers, Z Zhao, ... Cancer immunology research 3 (3), 288-295, 2015 | 180 | 2015 |
| Molecular pathways: clinical applications and future direction of insulin-like growth factor-1 receptor pathway blockade WT Iams, CM Lovly Clinical Cancer Research 21 (19), 4270-4277, 2015 | 179 | 2015 |
| Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas AY Helena, CS Sima, R Shen, S Kass, J Gainor, A Shaw, M Hames, ... Journal of thoracic oncology 10 (3), 431-437, 2015 | 130 | 2015 |
| Longitudinal cell-free DNA analysis in patients with small cell lung cancer reveals dynamic insights into treatment efficacy and disease relapse K Almodovar, WT Iams, CB Meador, Z Zhao, S York, L Horn, Y Yan, ... Journal of Thoracic Oncology 13 (1), 112-123, 2018 | 113 | 2018 |
| Clinical implications of circulating tumor DNA tumor mutational burden (ctDNA TMB) in non‐small cell lung cancer YK Chae, AA Davis, S Agte, A Pan, NI Simon, WT Iams, MR Cruz, ... The oncologist 24 (6), 820-828, 2019 | 107 | 2019 |
| Peroxisome proliferator‐activated receptor δ agonists inhibit T helper type 1 (Th1) and Th17 responses in experimental allergic encephalomyelitis S Kanakasabai, W Chearwae, CC Walline, W Iams, SM Adams, JJ Bright Immunology 130 (4), 572-588, 2010 | 103 | 2010 |
| Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations TA Rich, KL Reckamp, YK Chae, RC Doebele, WT Iams, M Oh, ... Clinical Cancer Research 25 (19), 5832-5842, 2019 | 73 | 2019 |
| A multidisciplinary housestaff-led initiative to safely reduce daily laboratory testing W Iams, J Heck, M Kapp, D Leverenz, M Vella, E Szentirmai, ... Academic Medicine 91 (6), 813-820, 2016 | 68 | 2016 |
| Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical … X Le, H Sakai, E Felip, R Veillon, MC Garassino, J Raskin, AB Cortot, ... Clinical Cancer Research 28 (6), 1117-1126, 2022 | 64 | 2022 |
| Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer☆ ML Hames, H Chen, W Iams, J Aston, CM Lovly, L Horn Lung Cancer 92, 29-34, 2016 | 64 | 2016 |
| OA03. 06 CodeBreaK 100/101: first report of safety/efficacy of sotorasib in combination with pembrolizumab or atezolizumab in advanced KRAS p. G12C NSCLC BT Li, GS Falchook, GA Durm, TF Burns, F Skoulidis, SS Ramalingam, ... Journal of Thoracic Oncology 17 (9), S10-S11, 2022 | 61 | 2022 |
| Improved prognosis and increased tumor-infiltrating lymphocytes in patients who have SCLC with neurologic paraneoplastic syndromes WT Iams, E Shiuan, CB Meador, M Roth, J Bordeaux, C Vaupel, KL Boyd, ... Journal of Thoracic Oncology 14 (11), 1970-1981, 2019 | 60 | 2019 |
| Cancer immunotherapy in a neglected population: the current use and future of T-cell-mediated checkpoint inhibitors in organ transplant patients YK Chae, C Galvez, JF Anker, WT Iams, M Bhave Cancer Treatment Reviews 63, 116-121, 2018 | 48 | 2018 |
| Smoking history and response to nivolumab in patients with advanced NSCLCs MD Hellmann, BC Creelan, K Woo, CS Sima, WT Iams, SJ Antonia, ... Annals of Oncology 25, iv429, 2014 | 48 | 2014 |
| Overexpression of adhesion molecules and barrier molecules is associated with differential infiltration of immune cells in non-small cell lung cancer YK Chae, WM Choi, WH Bae, J Anker, AA Davis, S Agte, WT Iams, M Cruz, ... Scientific reports 8 (1), 1023, 2018 | 41 | 2018 |
| Small cell lung cancer transformation as a mechanism of resistance to PD-1 therapy in KRAS-mutant lung adenocarcinoma: a report of two cases WT Iams, KE Beckermann, K Almodovar, J Hernandez, C Vnencak-Jones, ... Journal of Thoracic Oncology 14 (3), e45-e48, 2019 | 38 | 2019 |
